PIFLUFOLASTAT F-18 for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Jun 2019: Trial registered, NCT03976843
  2. 4 Dec 2019: Trial started, NCT03976843

The trials

NCT03976843: Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

State
Under way
Phase
Phase 2
People
175 taking part
Started
4 Dec 2019
Primary completion
19 Nov 2027
Arms
1/18F-DCFPyL PET/CT + radical prostatectomy
Results
None posted
  1. 6 Jun 2019: Trial registered
  2. 4 Dec 2019: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as 18F-DCFPyL, Pylarify, Pylarify truvu.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.